ATTO insider transaction filings
Attovia Therapeutics, Inc. — 16 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-28. Screen ATTO transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 16 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 13 legs across 8 filings by 17 insiders — 4,210,587 shares, $72,939,979 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 92 legs across 4 filings by 9 insiders — 423,228 shares, $9,006,631 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 55.
- Largest priced transaction: purchase of 588,235 shares @ $17.00 ($9,999,995) by Frazier Life Sciences XI, L.P., filed 2026-08-06.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
+3 more insiders in the window, not shown — every filing appears in the table below.
Recent Form 4 filings — Attovia Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-28 | 4/A | WALSH COLIN — Director | Purchase (P): 85,000 @ $21 · Sale (S): 988 @ $22.03 · Sale (S): 447 @ $21.87 · Sale (S): 1,332 @ $22.03 · Sale (S): 200 @ $22.05 · Sale (S): 1,556 @ $22.06 · +29 more | EDGAR |
| 2026-08-28 | 4/A | GOLDMAN SACHS GROUP INC GOLDMAN SACHS & CO. LLC GOLDMAN SACHS ASSET MANAGEMENT, L.P. Broad Street Principal Investments, L.L.C. WSLS OFFSHORE INVESTMENTS, SLP West Street Life Sciences I, L.P. WSLS EMP OFFSHORE INVESTMENTS, L.P. WSLS EMP ONSHORE INVESTMENTS, L.P. | Purchase (P): 85,000 @ $21 · Sale (S): 988 @ $22.03 · Sale (S): 447 @ $21.87 · Sale (S): 1,332 @ $22.03 · Sale (S): 200 @ $22.05 · Sale (S): 1,556 @ $22.06 · +29 more | EDGAR |
| 2026-08-13 | 4 | WALSH COLIN — Director | Purchase (P): 85,000 @ $21 · Sale (S): 988 @ $22.03 · Sale (S): 447 @ $21.87 · Sale (S): 1,332 @ $22.03 · Sale (S): 200 @ $22.05 · Sale (S): 1,556 @ $22.06 · +23 more | EDGAR |
| 2026-08-13 | 4 | GOLDMAN SACHS GROUP INC GOLDMAN SACHS & CO. LLC GOLDMAN SACHS ASSET MANAGEMENT, L.P. Broad Street Principal Investments, L.L.C. WSLS OFFSHORE INVESTMENTS, SLP West Street Life Sciences I, L.P. WSLS EMP OFFSHORE INVESTMENTS, L.P. WSLS EMP ONSHORE INVESTMENTS, L.P. | Purchase (P): 85,000 @ $21 · Sale (S): 988 @ $22.03 · Sale (S): 447 @ $21.87 · Sale (S): 1,332 @ $22.03 · Sale (S): 200 @ $22.05 · Sale (S): 1,556 @ $22.06 · +23 more | EDGAR |
| 2026-08-10 | 4 | Deep Track Biotechnology Master Fund, Ltd. — 10% owner Deep Track Capital, LP — 10% owner KROIN DAVID — 10% owner | Conversion (C): 1,957,138 · Conversion (C): 18,181,818 (derivative) @ $0 | EDGAR |
| 2026-08-10 | 4 | venBio Global Strategic Fund IV, L.P. — 10% owner | Conversion (C): 2,311,870 · Conversion (C): 821,998 · Conversion (C): 665,147 · Purchase (P): 382,352 @ $17 · Conversion (C): 21,477,273 (derivative) @ $0 · Conversion (C): 7,636,362 (derivative) @ $0 · +1 more | EDGAR |
| 2026-08-07 | 4 | Redmile Group, LLC — 10% owner Green Jeremy — 10% owner Redmile Biopharma Investments III, L.P. — 10% owner | Conversion (C): 782,854 · Purchase (P): 200,000 @ $17 · Purchase (P): 400,000 @ $17 · Conversion (C): 782,854 (derivative) | EDGAR |
| 2026-08-07 | 4 | Sanofi — 10% owner | Conversion (C): 782,855 · Purchase (P): 300,000 @ $17 · Conversion (C): 782,855 (derivative) | EDGAR |
| 2026-08-06 | 4 | Frazier Life Sciences XI, L.P. — 10% owner FHMLS XI, L.P. — 10% owner FHMLS XI, L.L.C. — 10% owner | Conversion (C): 1,749,192 · Conversion (C): 1,590,175 · Conversion (C): 1,189,940 · Conversion (C): 961,322 · Purchase (P): 588,235 @ $17 · Conversion (C): 16,250,000 (derivative) @ $0 · +3 more | EDGAR |
| 2026-08-06 | 4 | Odrowaz Zaneta — Chief Business Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | GOLD MITCHELL — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | You Angie — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | Attovia Therapeutics, Inc. — Chief Financial Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | Chen Hubert — Chief Medical Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | Veiby Petter — Chief Scientific Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | Attovia Therapeutics, Inc. — President and CEO, Director | Grant/award (A): 538,300 (derivative) @ $0 | EDGAR |
Recent 8-K events — Attovia Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-02 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ATTO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →